npj Precision Oncology (Nov 2024)

Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score

  • Christoph Arolt,
  • Andreas H. Scheel,
  • Margaret Dugan,
  • Robert Wild,
  • Vanessa Richartz,
  • Barbara Holz,
  • Johannes Brägelmann,
  • Svenja Wagener-Ryczek,
  • Sabine Merkelbach-Bruse,
  • Juergen Wolf,
  • Reinhard Buettner,
  • Luigi Catanzariti,
  • Matthias Scheffler,
  • Axel M. Hillmer

DOI
https://doi.org/10.1038/s41698-024-00744-1
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Our recently published K1N2-score robustly predicts KEAP1/NFE2L2-mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC might be a reliable alternative using 348 KEAP1/NFE2L2 mutation-enriched NSCLC. While TXNRD1 RNA testing was the best-performing single-gene test, the combination of single-gene screening and validation with the K1N2-score achieved the highest performance when predicting mutation status or pathway activation.